Summary
42 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 0.0 years of operating profit.
- It has been profitable 6 years in a row.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 17% a year over the last 3 years.
- Out of every 100 INR of revenue, only 3.6 INR is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 54.8 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 9.9% a year. Earnings per share fell by 17% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 INR of revenue goes
- Cost of sales 73 INR
- Sales and administration 18 INR
- Taxes and other 5.1 INR
- Net profit 3.6 INR
Net profit, industry median (Drug Manufacturers - General) 14 INR
Out of every 100 INR of revenue, 3.6 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.06%
- Paid out of profit
- 58%
You receive ₹3.00 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail